Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC-ACS (improving care for cardiovascular disease in China-acute coronary syndrome) project

被引:70
作者
Wang, Yintang [1 ]
Geng, Yu [1 ]
Zhang, Ou [1 ]
Xu, Qin [2 ,3 ]
Xue, Yajun [1 ]
Zhou, Boda [1 ]
Zhang, Ping [1 ]
Li, Aihua
Li, Bao
Xu, Biao
Han, Guangshu
Li, Bin
Liu, Bin
Wang, Bin
Fu, Bing
Yu, Bo
Yang, Bosong
Luo, Caidong
Wang, Changqian
Liu, Changyong
Liang, Chuanliang
Gao, Chuanyu
Lai, Chunlin
Wang, Chuntong
Zhang, Chunyan
Wu, Chunyang
Zhang, Congliang
Bin, Cui
Huang, Lan
Peng, Daoquan
Xu, Dawen
Wu, Di
Zhu, Dongmei
Chai, Dongsheng
Li, Dongyan
Tang, Fakuan
Xiao, Jun
Zhao, Fang
Huang, Fangfang
Meng, Fanju
Li, Fengwei
Gan, Fudong
Xu, Gang
Sang, Gengsheng
Ma, Genshan
Zhang, Guixia
Tao, Guizhou
Li, Guo
Chen, Guoduo
Xin, Guoqin
机构
[1] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Cardiol, 168 Litang Rd, Beijing 102218, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
关键词
P2Y12 receptor inhibitors; Non-ST-segment elevation acute coronary syndrome; Loading dose; Outcome; Therapy; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; EUROPEAN-SOCIETY; ARTERY-DISEASE; FOCUSED UPDATE; 2017; ESC; CLOPIDOGREL; ASPIRIN; ANGIOPLASTY; GUIDELINES;
D O I
10.1186/s40001-023-01025-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The association between P2Y12 receptor inhibitors reloading and in-hospital outcomes in non-ST-segment elevation acute coronary syndrome (NSTEACS) patients who were on chronic P2Y12 receptor inhibitors therapy remained underdetermined.Methods The Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS project) is a national registry active from November 2014 to December 2019. 4790 NSTEACS patients on chronic P2Y12 receptor inhibitors therapy were included. Cox proportional hazard models, Kaplan-Meier curves, and subgroup analyses were conducted.Results The NSTEACS patients who received reloading of P2Y12 receptor inhibitors were younger and had fewer comorbid conditions. The reloading group had a lower risk of major adverse cardiac events (MACE) (0.51% vs. 1.43%, P = 0.007), and all-cause death (0.36% vs. 0.99%, P = 0.028), the risks of myocardial infarction and major bleeding were not significantly different between patients with and without reloading. In survival analysis, a lower cumulative risk of MACE could be identified (Log-rank test, P = 0.007) in reloading group. In the unadjusted Cox model, reloading P2Y12 receptor inhibitors was associated with a decreased risk of MACE [HR, 0.35; 95% CI 0.16-0.78; (P = 0.010)] and all-cause death [HR, 0.37; 95% CI 0.14-0.94; (P = 0.036)]. Reloading of P2Y12 receptor inhibitors was associated with a decreased risk of MACE in most of the subgroups.Conclusions In NSTEACS patients already taking P2Y12 receptor inhibitors, we observed a decreased risk of in-hospital MACEs and all-cause mortality and did not observe an increased risk of major bleeding, with reloading. The differential profile in the two groups might influence this association and further studies are warranted.
引用
收藏
页数:11
相关论文
共 27 条
  • [1] Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Andreotti, Felicita
    Rocca, Bianca
    Husted, Steen
    Ajjan, Ramzi A.
    ten Berg, Jurrien
    Cattaneo, Marco
    Collet, Jean-Philippe
    De Caterina, Raffaele
    Fox, Keith A. A.
    Halvorsen, Sigrun
    Huber, Kurt
    Hylek, Elaine M.
    Lip, Gregory Y. H.
    Montalescot, Gilles
    Morais, Joao
    Patrono, Carlo
    Verheugt, Freek W. A.
    Wallentin, Lars
    Weiss, Thomas W.
    Storey, Robert F.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (46) : 3238 - +
  • [2] Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
    Cadroy, Y
    Bossavy, JP
    Thalamas, C
    Sagnard, L
    Sakariassen, K
    Boneu, B
    [J]. CIRCULATION, 2000, 101 (24) : 2823 - 2828
  • [3] ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison
    Capodanno, Davide
    Alfonso, Fernando
    Levine, Glenn N.
    Valgimigli, Marco
    Angiolillo, Dominick J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (23) : 2915 - 2931
  • [4] Collet JP, 2008, CIRCULATION, V118, P1225, DOI [10.1161/CIRCULATIONAHA.108.776757, 10.1161/CIRCULATIONAHA.108.191108]
  • [5] Collet JP, 2021, REV ESP CARDIOL, V74, DOI [10.1016/j.rec.2021.05.002, 10.1093/eurheartj/ehaa575]
  • [6] Importance of events per independent variable in proportional hazards analysis .1. Background, goals, and general strategy
    Concato, J
    Peduzzi, P
    Holford, TR
    Feinstein, AR
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (12) : 1495 - 1501
  • [7] Clopidogrel reloading for patients with acutemyocardial infarction already on clopidogrel therapy
    Doll, Jacob A.
    Li, Shuang
    Chiswell, Karen
    Roe, Matthew T.
    Kosiborod, Mikhail
    Scirica, Benjamin M.
    Wang, Tracy Y.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (03) : 193 - 200
  • [8] Pre-Treatment With Oral P2Y12 Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes Does One Size Fit All?
    Ferreiro, Jose Luis
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (08) : 918 - 920
  • [9] The Global Registry of Acute Coronary Events, 1999 to 2009-GRACE
    Fox, K. A. A.
    Eagle, K. A.
    Gore, J. M.
    Steg, Ph G.
    Anderson, F. A.
    [J]. HEART, 2010, 96 (14) : 1095 - 1101
  • [10] Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention
    Franchi, Francesco
    Rollini, Fabiana
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (08) : 807 - 809